ENOS Polyclonal Antibody

Product Specifications

Background

Produces nitric oxide (NO) which is implicated in vascular smooth muscle relaxation through a cGMP-mediated signal transduction pathway. NO mediates vascular endothelial growth factor (VEGF) -induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets. Isoform eNOS13C: Lacks eNOS activity, dominant-negative form that may down-regulate eNOS activity by forming heterodimers with isoform 1.

Synonyms

ENOS; ECNOS; Nitric oxide synthase, endothelial; Constitutive NOS; cNOS; EC-NOS; Endothelial NOS; NOS type III; NOSIII; NOS3

Gene ID

4846

Swiss Prot

P29474

Cellular Locus

Cytoplasm, Cell membrane

Host

Rabbit

Cross Reactivity

Human, Rat

Immunogen

1105-1202/1203

Target

ENOS

Clonality

Polyclonal

Conjugation

Unconjugated

Source

KLH conjugated synthetic peptide derived from human NOS-3

Applications

WB, ELISA, FCM, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Concentration

1ug/ul

Dilution

WB (1:300-5000), ELISA (1:500-1000), FCM (1:20-100), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)